CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.375
EU - Europa 3.493
AS - Asia 1.124
AF - Africa 52
SA - Sud America 43
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.323
CN - Cina 726
IT - Italia 689
DK - Danimarca 579
IE - Irlanda 507
SE - Svezia 416
FR - Francia 251
AT - Austria 245
UA - Ucraina 156
DE - Germania 141
FI - Finlandia 136
GB - Regno Unito 110
VN - Vietnam 98
BE - Belgio 77
IN - India 77
KR - Corea 68
NL - Olanda 48
CA - Canada 39
JP - Giappone 35
PL - Polonia 30
ES - Italia 28
AU - Australia 25
HK - Hong Kong 22
BR - Brasile 21
GR - Grecia 18
EG - Egitto 16
RO - Romania 15
TH - Thailandia 14
NG - Nigeria 13
RU - Federazione Russa 13
ZA - Sudafrica 11
ID - Indonesia 10
MX - Messico 10
PK - Pakistan 10
TR - Turchia 10
TW - Taiwan 9
UZ - Uzbekistan 9
CO - Colombia 8
EU - Europa 8
SG - Singapore 8
CH - Svizzera 7
SN - Senegal 6
IL - Israele 5
PT - Portogallo 5
CL - Cile 4
CZ - Repubblica Ceca 4
MY - Malesia 4
AR - Argentina 3
EC - Ecuador 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
KZ - Kazakistan 2
LK - Sri Lanka 2
ME - Montenegro 2
PE - Perù 2
QA - Qatar 2
BD - Bangladesh 1
BF - Burkina Faso 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 11.121
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.314
Chandler 978
Dublin 506
Beijing 432
Fairfield 339
Torino 312
Houston 286
Woodbridge 251
Nyköping 217
Vienna 201
Dearborn 195
Villeurbanne 190
Wilmington 183
Medford 141
Princeton 132
Ashburn 117
Cambridge 115
Fremont 102
Redwood City 95
Seattle 95
Jacksonville 93
Brussels 70
Turin 51
Boardman 46
Dong Ket 43
Boston 37
Pisa 37
Nanjing 34
Washington 31
Hangzhou 29
Milan 29
Shanghai 26
San Diego 23
Warsaw 23
Toronto 21
Guangzhou 20
Hebei 19
Hefei 19
Norwalk 18
Chengdu 17
Verona 16
Seoul 13
Abuja 12
Tokyo 12
Jinan 11
Mountain View 11
Cairo 10
Falls Church 10
Zhengzhou 10
Cinisello Balsamo 9
Hyderabad 9
London 9
Los Angeles 9
Central District 8
Edinburgh 8
Genoa 8
Kunming 8
Nanchang 8
Silver Spring 8
Chicago 7
Des Moines 7
New York 7
Phoenix 7
Taipei 7
Barcelona 6
Columbus 6
Jakarta 6
Medellín 6
Rome 6
Shenzhen 6
Tianjin 6
Athens 5
Cape Town 5
Chongqing 5
Esslingen am Neckar 5
Guiyang 5
Islamabad 5
Mumbai 5
Ottawa 5
Philadelphia 5
Aachen 4
Andover 4
Bakersfield 4
Buffalo 4
Changsha 4
Copenhagen 4
Dallas 4
Düsseldorf 4
Kharkiv 4
Lachine 4
Minneapolis 4
Munich 4
New Orleans 4
Paris 4
Rio De Janeiro 4
Rio de Janeiro 4
San Mateo 4
Stockholm 4
São Paulo 4
Upper Marlboro 4
Totale 7.278
Salva come PNG Salva come JPEG
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 378
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 354
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 234
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 222
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 203
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 194
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 181
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 180
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 178
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 174
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 173
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 167
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 166
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 161
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 161
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 157
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 155
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 147
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 145
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 144
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 143
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 143
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 141
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 134
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 132
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 132
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 130
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 128
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 128
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 128
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 127
Pharmacogenetics of ribavirin-induced anemia in HCV patients 126
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 123
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 117
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 115
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 113
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 113
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 111
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 106
Cannabinoids concentration variability in cannabis olive oil galenic preparations 104
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 102
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 98
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 98
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 94
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 93
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 92
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 91
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 91
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 90
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 89
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 88
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 86
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 85
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 82
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 81
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 78
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 77
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 77
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 76
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 76
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 75
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 73
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 72
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 72
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 71
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 69
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 66
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 66
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 65
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 65
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 65
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 64
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 63
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 63
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 60
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 60
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 59
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 58
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 58
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 57
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence 57
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 57
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 56
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 56
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump 56
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 56
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 55
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 54
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 52
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 51
Precision medicine for HIV: where are we? 51
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 50
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir. 49
Data on the stability of darunavir/cobicistat suspension after tablet manipulation 49
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 49
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals 48
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 48
Antiretroviral concentrations in the presence and absence of valproic acid 48
Totale 10.612
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.249
article - articoli 0
book - libri 0
conference - conferenze 4.108
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019711 0 0 46 67 53 68 48 87 20 125 117 80
2019/20201.956 39 40 49 138 183 369 168 109 179 257 192 233
2020/20211.445 164 75 49 89 114 103 107 52 105 115 188 284
2021/20222.441 176 193 196 196 156 210 181 152 114 129 387 351
2022/20232.816 248 233 71 257 250 650 193 239 323 61 191 100
2023/2024446 167 198 81 0 0 0 0 0 0 0 0 0
Totale 11.764